BPS3012 Applied Pharmaceutical Science: From Concept to Market

How BPS3012 is assessed

What BPS3012 covers

Follow the unit from concept-to-market case studies through emerging therapeutic technologies, then turn that science into the written inquiry and team poster assessments.

The unit begins with concept-to-market case studies, using semaglutide and lenacapavir to connect target biology with molecular design, formulation, manufacture, quality and clinical use.

It then examines emerging approaches likely to shape drug discovery and development, including model-informed development, artificial intelligence, systems pharmacology, stem cells, gene technology, epigenetic regulation, targeted protein degradation and RNA-targeted medicines.

The course is assessed through three official categories.

1 - Written is worth 30% and includes a future-medicines essay, a research-process statement and a concise review of course content. 2 - Project is worth 50% and centres on a team profile of a pharmaceutical company or research group, developed through planning, analysis, a scientific poster and presentation.

3 - Quiz / Test is worth 20%, split in the unit summary between a mid-semester test worth 15% and an online quiz worth 5%. No final examination is listed in the official assessment record.

The mid-semester test is described as a hard-copy paper with no access to materials or devices, using fill-the-gaps multiple choice, standard multiple choice and one short answer selected from topic options.

Preparation should therefore combine precise vocabulary with complete causal explanations. The larger assessments demand a different skill: synthesising evidence into a bounded judgement. The future-medicines essay must move from a real present problem to an evidence-supported direction, with novelty, benefits, drawbacks, impact and implementation hurdles.

The team project must convert reliable organisation research into a coherent poster and oral message for a defined audience.

Worked example · free

Turn an emerging-technology topic into an evidence-led future claim

Key terms

Inquiry-based learning

A learning approach in which students investigate questions, gather and evaluate evidence, make judgements and communicate conclusions rather than only reproduce supplied answers.

Concept-to-market pathway

The connected development route from therapeutic need and target biology through molecule, formulation, manufacture, quality evidence and clinical use.

Model-informed development

The use of quantitative models and simulations to integrate evidence and inform drug-development decisions while making assumptions and uncertainty explicit.

Population PK/PD

A modelling approach that describes typical pharmacokinetic or pharmacodynamic behaviour, variability between people and covariates that may explain that variability.

PBPK

Physiologically based pharmacokinetic modelling that represents organs, flows and biochemical processes to explore exposure under mechanistic scenarios.

Systems pharmacology

The study of how a therapeutic intervention propagates through interacting targets, pathways, cells, tissues and patient contexts.

Epigenetic reader

A protein that recognises a chromatin mark and helps translate that regulatory state into a transcriptional programme.

PROTAC

A bifunctional degrader that brings a target protein together with an E3 ligase to promote ubiquitination and proteasomal destruction.

Ternary complex

The three-part assembly of target, degrader and recruited E3 ligase whose geometry can determine productive ubiquitin transfer.

RNA targeting

Therapeutic modulation of RNA abundance, processing, translation, structure or interactions using oligonucleotides, cellular machinery or small molecules.

Therapeutic window

The range of exposure or biological effect in which benefit is achieved without unacceptable harm.

Evidence boundary

The limit beyond which a finding does not support a stronger claim, such as binding evidence that does not yet establish patient benefit.

BPS3012 FAQ

Questions students ask in each BPS3012 chapter

Why is semaglutide more than a receptor agonist story?

Its clinical use depends on engineered stability, albumin association, formulation, manufacture and quality as well as GLP-1 receptor action. Those features shape exposure, dosing and product reliability. Sequence modification and albumin association address degradation and clearance, while formulation must support the intended route. Manufacturing controls identity, impurities and aggregation. Evidence for each layer answers a different question, so receptor activity cannot stand in for a stable, reproducible product or demonstrated clinical benefit. Chapter 01 · Concept to Market Case Studies

What makes a model useful in drug development?

It must answer a defined decision question, integrate relevant evidence, expose assumptions, report uncertainty and be checked against observations. A technically complex model without a decision fit is not automatically useful. Fitness therefore depends on intended use: dose selection, interaction prediction and trial design may demand different structures and checks. State which output changes the decision, where inputs came from, which assumptions dominate and what external observation would show that the model has left its reliable domain. Chapter 02 · Model-Informed Drug Development

Is every artificial intelligence tool deep learning?

No. Deep learning is one subset of machine learning, which is itself a subset of artificial intelligence. Natural language processing names a language-related task area and can use several model types. In an evaluation, the category label is less important than the defined input, task, output and decision. Two systems both described as AI may require completely different data and validation. Avoid using the broad label as evidence of accuracy, novelty or pharmaceutical usefulness. Chapter 03 · Artificial Intelligence in Drug Discovery

When is a technology genuinely disruptive?

When it changes a defined workflow or decision and produces a measurable improvement against a real baseline. Novelty or speed in one local step is not enough if validation or adoption becomes the new bottleneck. Define the user, displaced constraint and outcome before applying the label. Then follow the workflow downstream: an improvement may move effort into interpretation, manufacture or implementation. Evidence of capability justifies a narrower claim than evidence of sustained prospective value. Chapter 04 · Disruptive Technologies and Systems Pharmacology

How does regeneration differ from repair?

Regeneration requires evidence of functional replacement and integration of cells or tissue. Repair may restore integrity or useful function through compensation or altered tissue without recreating the original structure. Distinguish the two by the claimed biological outcome and the measurements that support it. A marker associated with a cell identity is not enough to prove durable integration or restored organ function. Manufacturing consistency, survival, host response and long-term monitoring also shape whether an observed experimental effect can become a reliable therapy. Chapter 05 · Stem Cells and Gene Technology

Do epigenetic drugs edit DNA?

Not by default. They alter proteins that write, remove or read regulatory states, changing access and expression while leaving the DNA sequence unchanged unless a separate editing technology is involved. Explain the intervention through a causal chain: regulator engagement changes a chromatin interaction or mark, which alters a transcriptional programme and may change phenotype. Each link needs its own evidence. A broad expression response does not prove that every downstream effect is intended or therapeutically selective. Chapter 06 · Epigenetic Drug Discovery

How does a PROTAC differ from an inhibitor?

An inhibitor usually relies on continued target occupancy, while a PROTAC recruits degradation machinery to trigger removal of the protein. That event can persist after the degrader disengages. This event-driven logic can produce durable loss, but it does not guarantee superiority. Cellular entry, ternary-complex geometry, ligase availability, ubiquitination and proteasomal processing must all succeed. Compare depth, kinetics and recovery as well as binding, and distinguish true target loss from reduced expression or nonspecific toxicity. Chapter 07 · Targeted Protein Degradation

What determines the choice of RNA modality?

Start with the desired RNA change, then compare recognition mechanism, cellular machinery, tissue delivery, intracellular location, duration and specificity. Different modalities solve different molecular problems. Antisense approaches can alter processing or reduce RNA, RNA interference uses cellular silencing machinery, and small molecules can recognise structured RNA. The choice should follow the target and required outcome. A familiar modality is not preferable if it cannot reach the relevant tissue, cell and compartment. Chapter 08 · RNA-Targeted Medicines

How narrow should the essay topic be?

It should be narrow enough to make one defensible future judgement with evidence, counterarguments and implementation hurdles. A broad technology label usually needs a disease, delivery or decision boundary. Test the scope by writing one sentence that names the present problem, recommended direction, intended setting and principal condition. If the sentence cannot be evaluated against evidence within the word limit, narrow it again. A focused question creates space for analysis instead of a catalogue of technologies. Chapter 09 · Future Medicines Essay

What should the organisation profile analyse?

Investigate the problem addressed, scientific capability, translation into products or research, comparative position and important scientific or operational risks. Select evidence that supports a clear judgement. Separate what the organisation says about itself from independent evidence of maturity or impact. A shared log should record each claim, source, evidence level and intended poster use. That process helps the team reconcile inconsistent findings and prevents promotional language from becoming an unsupported analytical conclusion. Chapter 10 · Inquiry Project and Scientific Poster

How to prepare for the assessments

Build one evidence matrix for the semester with columns for intervention, mechanism, translation barrier, evidence and limitation. Use it to compare semaglutide, lenacapavir, MIDD, AI, cell and gene technologies, epigenetic drugs, degraders and RNA medicines. For the mid-semester test, practise connected gap passages, explain why distractors fail, and write ten-minute causal short answers.

For the written assignment, choose a problem narrow enough to analyse, write the hurdle into the thesis, organise sources by argumentative role and reverse-map the finished draft to the rubric. For the team project, keep a shared evidence log, agree on one poster message before designing panels, rehearse transitions and prepare direct answers to difficult questions.

Always distinguish what evidence shows from what it merely suggests.